BioMed Research International / 2015 / Article / Tab 1 / Review Article
Prognostic Value of MACC1 in Digestive System Neoplasms: A Systematic Review and Meta-Analysis Table 1 Summary of eligible studies included for meta-analysis.
Study design Number of patients Cancer subtype TNM staging Sample MACC1 detection MACC1 cut-off High MACC1 proportion Outcome HR obtainment HR 95% CI Stein et al., 2012 [12 , 13 ] C 294 CRC I–IV Blood qRT-PCR Median value 147/294 OS Estimated 1.260 0.450–3.530 Zhang et al., 2012 [14 ] R 90 CRC I–IV Tissue IHC Score ≥ 5 78/90 OS Estimated 2.240 1.220–4.100 Kang et al., 2013 [15 ] R 317 CRC I–IV Tissue IHC Positive cells > 20% 176/317 OS Reported 2.560 1.830–3.570 Zhen et al., 2014 [16 ] R 323 CRC I–IV Tissue IHC Staining score = 6 169/323 OS Reported 1.410 0.737–2.699 Ge et al., 2011 [17 ] R 128 GC I–IV Tissue IHC Positive cells ≥ 20% 61/128 OS Reported 0.621 0.380–1.014 Guo et al., 2013 [18 ] R 98 GC I–IV Tissue IHC Score > 3 60/98 OS Estimated 1.330 0.640–2.760 Wang et al., 2013 [5 ] R 361 GC I–IV Tissue IHC Score ≥ 3 280/361 OS Reported 2.217 1.311–3.049 Zhu et al., 2013 [9 ] R 85 EC I–III Tissue IHC Score > 2 47/85 OS Reported 2.250 1.180–4.280 Yang et al., 2013 [19 ] R 120 HCC N/A Tissue qRT-PCR Median value 60/120 OS Reported 1.842 1.201–2.514 Qiu et al., 2011 [10 ] R 128 HCC I–III Tissue qRT-PCR Threshold value 57/128 OS Reported 2.230 1.257–3.957 Qu et al., 2012 [20 ] R 234 HCC N/A Tissue qRT-PCR
Value > 0.006 73 105/234 OS Reported 1.508 1.079–1.835 Ding et al., 2013 [21 ] R 66 HCC I–IV Tissue IHC Positive cells > 50% 33/66 OS Estimated 2.190 0.870–5.530 Xie et al., 2013 [22 ] R 308 HCC I–IV Tissue IHC Score > 6 126/308 OS Reported 4.823 3.257–6.893 Ji et al., 2014 [23 ] R 60 HCC I–IV Tissue IHC Score ≥ 3 41/60 OS Reported 2.827 1.030–7.759 Gao et al., 2014 [24 ] R 160 HCC N/A Tissue qRT-PCR ROC curve 72/160 OS Reported 2.280 1.453–3.580 Stein et al., 2009 [3 ] C 60 CRC I–III Tissue qRT-PCR Median value 30/60 MFS Estimated 3.340 1.820–6.130 Isella et al., 2013 [25 ] R 64 CRC N/A Tissue qRT-PCR
>−1.30 51/64 RFS Estimated 1.880 1.210–2.920 Kawamura et al., 2012 [26 ] R 52 CRC II-III Tissue qRT-PCR 0.261 18/52 RFS Estimated 2.100 1.030–4.300
Study design is described as consecutive patients (C) or retrospective (R). Cancer subgroups include colorectal cancer (CRC), gastric cancer (GC), esophageal cancer (EC), and hepatocellular cancer (HCC). Clinical outcomes include overall survival (OS), metastasis-free survival (MFS), relapse-free survival (RFS), and disease-free survival (DFS). MACC1 measurement is categorized as quantitative real-time polymerase chain reaction (qRT-PCR) and immunohistochemistry (IHC) group.
